Abstract
During the last few decades, we have witnessed major improvements in the therapy of pulmonary arterial hypertension (PAH). PAH is characterized by abnormal remodeling of the pulmonary artery (PA) and increased PA pressures, resulting in a high premature mortality. Intravenous epoprostenol was the first effective approach toward improving the symptoms and survival of PAH patients. New prostanoids have also exhibited substantial clinical benefits; however, their long-term effects are under investigation. Endothelin-receptor antagonists and sildenafil have increased the lineup of therapeutic options against PAH. Combination therapy using these drugs is promising and is currently undergoing scrutiny in large clinical trials. An extensive analysis of the molecular mechanisms of PAH will produce novel targeted therapies. Most of the promising molecules target the inflammatory and proliferative processes underlying pathological PA remodeling. Interestingly, drugs used for other diseases, such as statins, Rho-kinase inhibitors, imatinib mesylate, may control the pathological vascular remodeling of PAH. Gene and cell therapy using vectors expressing prostacyclin synthase, endothelial nitric oxide synthase, or vascular endothelial growth factor are also promising strategies. However, the efficacy and safety of these approaches should be further tested in clinical trials. Genetic studies revealed some crucial genetic dispositions of familial PAH, although their pathobiological roles have not yet been fully clarified. Collaboration for integrated research will address these issues and generate greater clinical benefits for PAH patients.
Keywords: Pulmonary arterial hypertension, treatment, prostacyclin, endothelin, sildenafil, gene therapy, inflammation, proliferation
Current Medicinal Chemistry
Title: Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Volume: 14 Issue: 6
Author(s): Takayuki Ito, Keiya Ozawa and Kazuyuki Shimada
Affiliation:
Keywords: Pulmonary arterial hypertension, treatment, prostacyclin, endothelin, sildenafil, gene therapy, inflammation, proliferation
Abstract: During the last few decades, we have witnessed major improvements in the therapy of pulmonary arterial hypertension (PAH). PAH is characterized by abnormal remodeling of the pulmonary artery (PA) and increased PA pressures, resulting in a high premature mortality. Intravenous epoprostenol was the first effective approach toward improving the symptoms and survival of PAH patients. New prostanoids have also exhibited substantial clinical benefits; however, their long-term effects are under investigation. Endothelin-receptor antagonists and sildenafil have increased the lineup of therapeutic options against PAH. Combination therapy using these drugs is promising and is currently undergoing scrutiny in large clinical trials. An extensive analysis of the molecular mechanisms of PAH will produce novel targeted therapies. Most of the promising molecules target the inflammatory and proliferative processes underlying pathological PA remodeling. Interestingly, drugs used for other diseases, such as statins, Rho-kinase inhibitors, imatinib mesylate, may control the pathological vascular remodeling of PAH. Gene and cell therapy using vectors expressing prostacyclin synthase, endothelial nitric oxide synthase, or vascular endothelial growth factor are also promising strategies. However, the efficacy and safety of these approaches should be further tested in clinical trials. Genetic studies revealed some crucial genetic dispositions of familial PAH, although their pathobiological roles have not yet been fully clarified. Collaboration for integrated research will address these issues and generate greater clinical benefits for PAH patients.
Export Options
About this article
Cite this article as:
Ito Takayuki, Ozawa Keiya and Shimada Kazuyuki, Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension, Current Medicinal Chemistry 2007; 14 (6) . https://dx.doi.org/10.2174/092986707780059562
DOI https://dx.doi.org/10.2174/092986707780059562 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology The Associations of Dietary Acid Load with Insulin Resistance and Type 2 Diabetes: A Systematic Review of Existing Human Studies
Recent Patents on Food, Nutrition & Agriculture Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Microcirculation in Hypertension: An Update on Clinical Significance and Therapy
Current Vascular Pharmacology Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Prediction of Bioactive Compound Pathways Using Chemical Interaction and Structural Information
Combinatorial Chemistry & High Throughput Screening CRP Pro-inflammatory Signalling in Atherosclerosis: Myth or Reality?
Current Signal Transduction Therapy Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Ghrelin and Motilin in the Gastrointestinal System
Current Pharmaceutical Design Musculoskeletal US: Taking the Management of Psoriatic Arthritis to a New Horizon
Current Rheumatology Reviews Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Editorial [Hot Topic: Progressive and Unconventional Pharmacotherapeutic Approaches to Alzheimers Disease Therapy (Guest Editors: Stuart Maudsley & Wayne Chadwick)]
Current Alzheimer Research